For approximately 65 million people in the world with epilepsy, antiepileptic drugs (AEDs) are the mainstay of treatment.
1 Lamotrigine (LTG) is a nonenzyme inducing AED with favorable pharmacokinetics, approved for use by the Food and Drug Administration (FDA) in epilepsy as well as bipolar disorder. From May 2009 to April 2010, approximately 9 million prescriptions were dispensed from outpatient pharmacies. 2 In epilepsy, it has proven to be effective in a wide variety of seizure types and patient groups (2 years of age and older), with clinical applicability in focal seizures and in generalized seizures associated with both genetic epilepsy and the Lennox-Gastaut syndrome. Both the efficacy and safety profile of LTG have been defined by numerous clinical studies. 3 Compared with other first-line AEDs, LTG is well tolerated with little sedation or cognitive impairment, weight neutrality, and a favorable psychotropic profile. A recent large randomized comparative effectiveness trial found LTG as the drug of first choice for patients with presumed partial (focal) epilepsy. 4 Since efficacy among AEDs does not differ for common epilepsy syndromes, tolerability becomes a critical factor in drug selection. 3 Adverse effects have long been recognized with all AEDs. 5 Upon its release in 1994, rash hampered the use of LTG. A black box warning in the prescribing information reflected the possibility of serious rash in pediatric (approximately 0.8%) and adult patients (0.3%) with epilepsy. Rash occurred in adults with bipolar disorder too, but at a rate of only 0.08%-0.13%. Subsequent to the initial information on rash frequency from pivotal trials, changes in dosing regimens made the rash risk comparable to other AEDs. 6 Other serious safety issues associated with the use of LTG included reports of isolated cleft lip and palate, escalating the pregnancy risk from Category C to Category D. In addition, LTG is included in a class warning by the FDA that the use of AEDs may increase the risk of suicidal thoughts or behavior. Now aseptic meningitis has been added to the Warnings and Precautions and Patient Counseling Information sections of LTG labeling instructions.
It is not uncommon for serious adverse drug reactions to be discovered after a drug has been marketed for some time. Serious adverse events associated with felbamate and topiramate were not discovered until long after drug approval. Glaucoma is an example of an adverse reaction that is considered type B, often idiosyncratic or allergic. Most adverse events are type A and are predictable, related to the drug's action, dose-related, and are often well characterized during randomized placebo-controlled trials. The relationship of LTG to aseptic meningitis 2 is supported by the occurrence soon after initiation, atypical and identifiable signs in this population, and resolution after discontinuation but recurrence on re-exposure. In contrast, the visual field disturbance seen with vigabatrin was not identified until nearly 100,000 patients were exposed to the drug, despite the fact that it affects up to 50% of exposed patients. 7 While visual field defects were thought to be common among patients with epilepsy, it was not easily identifiable: many were asymptomatic, it did not occur in close temporal relationship to drug initiation or reverse with drug discontinuation.
In this issue of Neurology ® , the relationship between LTG and aseptic meningitis is explored.
2 Severe headache, meningismus, and low-grade fever are clinical signs that suggest meningitis to most neurologists. Aseptic implies the lack of a bacterial source and includes viral and noninfectious etiologies such as autoimmune conditions. Infrequently, it occurs as a side effect of medications. However, drug-induced aseptic meningitis has been linked to numerous agents and exists largely in the form of anecdotal case reports. 8 Twenty-five of 40 patients had objective evidence of meningitis though CSF profiles were sometimes incomplete or raised the possibility of a nondrug source. 2 Headache is a cardinal symptom of meningitis yet it is also a primary side effect from LTG use. Lumbar puncture (LP) is required to diagnose men-ingitis. Most clinicians can distinguish the signs of a headache associated with meningitis. In the case of the study cited, while complex contributions may occur from more than one source (i.e., amoxicillin, LTG, and autoantibodies), treatment remains targeted for infectious disease initially. 9 The article by Simms et al. 2 appears to demonstrate a clear association between LTG and aseptic meningitis.
Prospective data with more new AED exposures will optimize the number of exposures to provide a proportioned analysis and minimize the effect of selective reporting to provide a true prevalence for a link with this adverse reaction. The report also justifiably reinforces the need for AED surveillance programs so that recognizing rare adverse reactions will alert users and prescribers to potential serious morbidity and mortality (i.e., felbamate). To what degree premorbid risk factor identification (i.e., HLA-B*1502 association with the risk of rash from carbamazepine) may avert the consequences of aseptic meningitis remains to be seen. We know that 16 -51 new cases will be identified yearly for every 100,000 people. AEDs are potentially life-saving in epilepsy and life-changing in other conditions such as mood disorders, migraine, and neuropathic pain. With each new AED adverse reaction comes more responsibility. With rash, the clinical sign is visible to the patient and to physicians. For Ͼ24,000 infants born to women with epilepsy yearly, 10 LTG remains a favorable choice with a relatively low risk of fetal malformations. The risk of suicidality is shared with AEDs as a class though the favorable effect upon mood is recognized. While the association of LTG with aseptic meningitis requires recalibrating the scale, the balance of benefit remains. The essential role of neurologists in evaluating risks and benefits with the latest "ding" for LTG should not deter the practical physician in guiding patients to the choice of AED that optimizes the greatest good overall. 
